Click here to join

Investors & Media

What's new.

Press releases

Press releases.

Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer

January 4th 2023
press releases

Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer

December 23rd 2022
press releases

Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha

December 8th 2022
press releases

Investor updates

Investor updates.

Investor Update - November 2022

November 17th 2022
investor updates

Investor Update ASCO 2022 Special Edition June 2022

June 17th 2022
investor updates

Investor Update - February 2022

February 18th 2022
investor updates

Analyst reports

Analyst reports.

Bell Potter - Analyst Outlook & Stock Picks for 2023

December 14th 2022
analyst reports

Wilsons - Healthcare in 2023: Our Top Six

December 7th 2022
analyst reports

Bell Potter - Immutep (IMM): Manufacturing process established for IMP761 (autoimmune disease targeting antibody) (Analyst: Dr Tara Speranza)

For a copy of this analyst report please contact your Bell Potter advisor.

December 6th 2022
analyst reports